Companies/Cannabis Suisse Corp.

Company profile

Cannabis Suisse Corp.

OTC: CSUI · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Jacksonville, CACIK 0001680132Reports USD

#1093 of 1,394 Healthcare companies by revenue26th-percentile growth

EA Score

38D

FH 30DQ 46GM 48SS 32

v0.1 · 65/100 weight · provisional

↑ 3-yr revenue growth, disclosure history · ↓ balance-sheet leverage, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$456.1k

Employees

—

Market cap

$643.2k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$22.5k$22.5k2025

Net income-$456.1k-$456.1k2025

Operating income-$288.0k-$288.0k2025

Total assets$635.1k$635.1k2025

Liabilities$2.4M$2.4M2025

Equity-$1.8M-$1.8M2025

Revenue trend

FY2018 – FY2025 · USD

$6.5k

FY18

$7.5k

FY19

$242.7k

FY20

$50.9k

FY21

$7.8k

FY22

$10.0k

FY23

$30.0k

FY24

$22.5k

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Rental Income100%

By geography

Not disclosed.

The read

Cannabis Suisse Corp. booked $22.5k in FY2025 revenue, contracting 25% year over year — slower than 74% of Healthcare companies we track, at a -2027.3% net margin.

Peers · Healthcare

Medical Care Technologies Inc.——Clearside Biomedical, Inc.——StageZero Life Sciences Ltd.——MYND Life Sciences Inc.——

Key facts

CEOScott W. Mcalister

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersJacksonville, CA

ExchangeOTC: CSUI

Employees—

IPO date2019-05-10

Latest filings

10-Q2026-04-20 10-Q2026-01-09 10-Q2025-10-10 10-K2025-09-12 10-Q2025-04-17 10-Q2025-01-13 10-Q2024-10-15 10-K2024-09-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.